Age >= 6 years at the NCI clinical center (>= 18 years at other participating sites)
Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0 or 1\r\n* Use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
Patient is at least 18 years of age
Be ?18 years of age.
Age ? 18 years at time of informed consent
Parts A & C: patients must be >= 12 months and < 18 years of age at the time of study enrollment
Parts B1-B6, B8, D1-D6, E3, E4: patients must be >= 12 months and =< 30 years of age at the time of study enrollment
Part B7: patients must be >= 12 months and < 18 years of age at the time of study enrollment
Age 50.0-75.0 years.
Must be ? 18 years of age.
Age ? 10 years
Age of 18 years or older; in addition, patients age 12 to 17 years may enroll beginning in Cohort 2 if weight ? 40 kg
A serum creatinine based on age/gender as follows:\r\n* =< 0.6 mg/dL (patients age 1 to < 2 years)\r\n* =< 0.8 mg/dL (patients age 2 to < 6 years)\r\n* =< 1 mg/dL (patients age 6 to < 10 years)\r\n* =< 1.2 mg/dL (patients age 10 to < 13 years)\r\n* =< 1.4 mg/dL (female patients age >= 13 years)\r\n* =< 1.5 mg/dL (male patients age 13 to < 16 years)\r\n* =< 1.7 mg/dL (male patients age >= 16 years)
Patients with body mass index (BMI) < 3rd percentile for age, as defined by WHO criteria for patients 1-2 years of age and Centers for Disease Control and Prevention (CDC) criteria for patients > 2 years of age, are not eligible
Participants who are less than 10 years of age at start of maintenance chemotherapy
Part A1: Patients must be >= 12 months and =< 21 years of age at the time of study enrollment
Standard risk 1: Patient must be < 11 years of age at enrollment
Standard risk 2: Patients must be >= 11 and < 25 years of age at enrollment
Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
Hemoglobin >= 8 g/dL for patients =< 16 years of age; >= 9 g/dL for patients > 16 years of age; Note: no transfusions are permitted 7 days prior to laboratory studies to determine eligibility
Efficacy Phase: Patients must be =< 40 years of age at the time of enrollment
Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
Patients must be >= 18 years of age
Age >= 14 years (>= 18 years in Germany)
Age ?18 years (or per national guidelines).
Age 18 years or above
Subjects must be age ? 21 years at initial diagnosis
? 18 years of age
Age ? 18 years.
Age ?18 years.
Subject is at least 18 years of age.
Age >= 18 years.
Subjects must be age ? 21 years at initial diagnosis
Men and women ?18 years of age
Adults (Age ? 18 years)
Subjects must be ?18 years of age.
Male or females with an age ? 18 years.
Age ? 18
Age ? 18 years of age
Be > 18 years of age on day of signing informed consent
Age >/=18 years at the time the ICF is signed
Age . 18 years old at the time of signing the informed consent
Age >/= 18 years;
Age > 18 years.
Subjects ? 18 years of age.
Age: 18 years
Patients must be ?18 years of age
At least 18 years of age
Age ?18 (or age ? 20 of age as required by local regulation).
? 18 years of age
Adults age 18-80 years
Age >21 years
Age > or = 21 years
?18 years of age
Age ? 18 years
COHORT 1: Be >= 18 years of age on day of signing informed consent
COHORT 2: Be >= 65 years of age on day of signing informed consent
18 years of age or order
Subject is at least 18 years of age.
Age ? 15 and < 41 years
Be > 6 months and < 18 years of age
Age ?18 years
Age ?18 years.
Age ? 18 years.
Patients age ?18 years at signing the informed consent.
Must be ? 18 years of age at the time of signing the ICF.
Age ? 18 years
Subjects ?18 years of age for solid tumor; in the case of midline carcinoma with NUT rearrangement. subjects may be ?16 years of age.
Patients must fit into one of the following categories:\r\n* Age >= 18 years to < 60 years with a cumulative illness rating scale (CIRS) score >= 6 OR deemed ineligible for cytotoxic chemotherapy by the treating investigator\r\n* >= 60 years
Age ?18 years
Age>= 50
Men and women ? 18 years of age.
Lansky >= 50% for patients =< 10 years of age or Karnofsky >= 50% for patients > 10 years of age
Age above or equal to 18 years
Pts must be ? 18 years of age
Must be less than 30 years of age at time of original diagnosis
Karnofsky >= 50% for patients > 10 years of age
Age >18 years.
?18 years of age.
Age > 18 years.
Be ?18 years of age.
Adequate performance status: Lansky ? 50 for patients < 16 years of age
Men and women ? 18 years of age.
Ambulatory and ?18 years of age.
?18 years of age.
Patients age ?18 years at signing the informed consent.
At least 18 years of age at the time of signing the informed consent form.
Post-menopausal (>= 60 years of age or with follicle stimulating hormone [FSH] > 30 IU/L if age 50-59)
Age ?18 years
Age >18 years and ?75 years.
Age ?60 years; or
Subjects > 10 years of age: Karnofsky >= 50%; Subjects =< 10 years of age: Lansky scale >= 50%
St. Jude patients must be between 2 years and =< 21 years of age, on therapy (active patient), or within 3 years of completion of therapy; patients treated at collaborating sites must be =< 24 years old
Male or female participants age ?18 years (or any age ?18 years if that age is considered to be an adult per the local jurisdiction) at the time of informed consent
? 18, but < 75 years of age
Age >/= 18 years
INCLUSION - PROCUREMENT: The first six (6) patients treated on the study should be adults (? 18 years [yrs] of age); six adolescents (age 12-18) should be treated before children (? 3 yrs of age) are eligible
18 years of age at the time of consenting.
Age ?18 years .
Patients ?12 years of age
Subjects must be at least 1 and less than or equal to 18 years of age at the time of study entry.
Age >= 21 years
Age ? 18 years
Age ? 18.0 years and < 66.0 years at the time of enrollment.
Patients =< 25 years of age will be eligible for the pre-surgical cohort; patients between 18-25 years of age will be treated at the adult Food and Drug Administration (FDA)-approved dose of 960 mg BID and can be enrolled immediately; patients less than 18 years of age will be enrolled and treated at the pediatric MTD once it is defined in the safety cohort
Patients =< 25 years of age with evaluable disease will be eligible for the expansion cohort; patients between 18 and 25 years of age will take adult dose of 960 mg BID and are eligible at the initiation of the trial; patients less than 18 years of age will take the MTD once it is defined in the safety cohort
Between 6 months and <18 years of age (or between 3 years and <18 years of age for rrcHL participants) on day of signing informed consent/assent (the first 3 participants dosed in Part 1 are to be ? 6 years of age)
Lansky Play Scale ?50 for participants from 6 months up to and including 16 years of age; or Karnofsky score ?50 for participants >16 years of age
Age ?18 years old
Male or female patients age ? 18 years of age at the time of informed consent
Age ? 18 years.
Subject is ?18 years of age at the time of signing the study informed consent.
Age at least 18 years.
Is of age ? 18 years
Male or female, ?18 years of age (?20 years of age in Taiwan)
Patient is < 75 years of age at time of enrollment.
? 18 years of age
Age ? 18 years.
Age > 18 years
Men and women at least 18 years of age
Age ? 18.
Children under the age of 18
Participants with 1 to less than (<) 18 years of age (Part 1 only), or 1 to 30 years of age, inclusive, if initial diagnosis of mature B-cell non-Hodgkin lymphoma (NHL) occurred at <18 years of age (Part 2 only)
?18 years of age.
Patients must be ? 45 years of age
Age ? 18 years.
Must be ? 18 years of age at the time of signing the ICF.
Age: ? 21 years at the time of study entry.
Age between 18 and 70 years (both inclusive).
? 18 years of age
Age >= 18 years or age of majority at the participating site, whichever is greater
Age ?18 years.
Age +/> 70
?18 years of age.
Age ?18 years and ?80.
Subject is > 22 years of age.
? 18 years of age.
Patients must be less than 18 years of age at the time of diagnosis.
Normal cardiac stress test for patients over 50 years of age
45 years of age or less.
Age ?18 years. Because no dosing or adverse event data are currently available on the use of ipilimumab or indoximod in patients <18 years of age, children are excluded from this study.
Age > 18 years
DONOR: age >= 12 and =< 75 years
Must be > = 18 years of age.
Age ? 12 months and < 18 years
Age >/= to 18 years
Must be at least 18 years of age.
Subjects must have a performance status of > 50%; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
Age ?18 years
Because no dosing or adverse event data are currently available on the use of enzalutamide and CRLX101 in patients < 18 years of age and prostate cancer is not common in children < 18 years of age, children are excluded from this study.
Age ? 18 years
? 18 years of age
Age ?18 years on the day of signing informed consent.
Patients who are ? 18 years of age.
Age ? 18 years
Age >18 years
At least 18 years of age.
Age >= 1 year and < 25 years at the time of screening; exception: participants with recurrent, progressive, or refractory medulloblastoma and are >= 1 and < 40 years of age at the time of study screening are eligible for screening
STRATUM A: Age >= 1 year and < 25 years at the time of screening
STRATUM B: Age >= 1 year and < 25 years at the time of study enrollment
STRATUM C: Age >= 10 years and < 40 years at the time of study enrollment
Men and women of age ?18 years.
Age ? 18 years.
Age ? 18 years
Men and women of age ?18 years.
2 to less than 19 years of age.
Karnofsky ? 50 for patients ? 16 years of age, and Lansky ? 50 for patients < 16 years of age.
Platelet count ? 100,000/mm3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment). Renal Function: • Creatinine clearance or radioisotope glomerular filtration rate (GFR) ? 70mL/min/1.73 m2 or normal serum creatinine based on age as shown below or GFR > 70ml/min/1.73m^2: Age < 5 years: 0.8 mg/dL maximum Age 5 to < 10 years: 1.0 mg/dL maximum Age 10 to < 15 years: 1.2 mg/dL maximum Age > 15 years: 1.5 mg/dL maximum Liver Function:
Age ?18 years at the time of informed consent.
At least 18 years of age
Age ? 18 years old at the time of signing the informed consent
Patient is at least 18 years of age.
Age >=18 years at time of signing Informed Consent Form
Age >18 years and ? 70 years at the time of enrollment
Subjects must ?18 years of age
At least 18 years of age.
Participant must be >= 18 years of age.
0 to 2 for Participants >= 75 years of age or
0 to 3 for Participants >= 18 to 74 years of age.
Age > 55 years with no menses for 12 or more months without an alternative medical cause.
Age ?12 years old
The participant has a Lansky (<16 years of age) or Karnofsky (?16 years of age) performance score of at least 50.
Patients must be ? 18 years of age.
Age ?18 years
Patient must be > 18 years of age.
Patient must be ?1 year and <75 years of age at screening and undergoing allogeneic HSCT.
? 12 years of age
Age ? 18 years.
Be ? 18 years of age on day of signing informed consent.
Donor age >= 18 years
Men over 18 years of age.
Age ?18 years at the time of signing informed consent.
Age >= 18 years
Age ?18 years
Age >21 years
0 for (age <61 years), +2 for (age 61-70 years), +4 for (age >71 years).
Age >75.
Age ? 18 years
Be ? 18 years of age at time of consent
Patient is at least 18 years of age and <90 years of age at the time Informed Consent is signed.
Karnofsky > 50 for patients > 16 years of age and Lansky > 50 for patients =< 16 years of age
Age ?18 years
be ?18 years of age;
Patients must be ? 18 years of age.
Age ? 18 years
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 or Karnofsky >= 60% in patients > 16 years of age, Lansky >= 60 for patients =< 16 years of age
Age ?18 years at the time of informed consent
At least 18 years of age.
Patients >= 18 years of age with relapsed/refractory Ph-positive ALL.
Age ?18 years.
Subject is ?18 years of age at the time of signing the study informed consent.
The pediatric cohort is defined as age younger than 18 years.
Age 18 or more years
At least 18 years of age.
Age ? 18 years at the time of consent.
Females ?18 years of age
Age ?18 years;
Subjects ? 18 years of age at screening
? 75 years of age OR
of 0 to 2 for participants ? 75 years of age or
of 0 to 3 for participants between 18 to 74 years of age.
Age > 55 years with no menses for 12 or more months without an alternative medical cause.
DONOR: At least 18 years of age
Age 27- 69 at enrollment
Age 12 to 65 years
Patients must be at least 18 years of age
Patient is at least 18 years of age
At least 18 years of age.
Patients must be at least 18 years of age.
ECOG Performance Status (PS) of 0, 1 or 2. For newly diagnosed AML patients < 75 years of age, ECOG 0-3; for ? 75 years of age, ECOG 0-2.
Age ?18 years
Men and women, ? 65 years of age.
Minimal limitation on activities of daily living as measured by Karnofsky ? 50 for participants > 16 years of age or Lansky ? 50 for participants ? 16 years of age.
Age: Male or female age ? 2 years and < 22 years unless enrolled in Part E
Subject is ?18 years of age
DONOR: Age > 14 years
?18 years of age
Patients ?18 years of age at the time of signature of the ICF
Age 40 years or older; this age cutoff is justified because breast cancers in women under the age of 40 are known to have a significantly higher risk of IBTR presumably due to underlying biologic differences
Age:\r\n* Phase 1: >= 6 and =< 21 years of age at time of enrollment\r\n* Phase 2: >= 6 and =< 21 years of age at diagnosis
Minimum age of 18 years
Adults ?18 years of age
Age ? 18 years.
Age > 18 years.
Age ? 18 years old (? 20 years old in Japan);
Age ?18 years
Age ?18 years
DONOR: At least 18 years of age
Adults ?18 years of age
Age ? 16 years
Patient age criteria: age >= 18 and =< 45 years (myeloablative regimen 1; age >= 18 and =< 80 years (nonmyeloablative regimen 2) at the discretion of the investigator(s); age >= 18 and =< 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy may receive reduced intensity regimen 3
< 70 years of age with no matched 5/6 or 6/6 sibling donor - patients >= 70 and =< 75 years of age may be eligible if they have a co-morbidity score =< 2
Age > 18
Age ?18 years at the screening visit.
Age 18 or more years
Post-menopausal defined as\r\n* Age >= 55 years and 1 year or more of amenorrhea\r\n* Age < 55 years and 1 year or more of amenorrhea with an estradiol assay < 20 pg/mL\r\n* Surgical menopause with bilateral oophorectomy
Age * 18 years
DONOR: Age >= 18 and =< 70 years
DONOR: Age 18 to 70 years of age
Appropriate written consent – adult or parent/guardian if patient is < 18 years of age and minor information sheet if patient is > 8 years of age
Age >= 40 to < 75 years; patients 18 to 39 years of age will be eligible only if the investigator has determined that the patient has comorbidity(ies) precluding conventional allogeneic transplantation with full intensity myeloablative conditioning
Be 18 years of age on day of signing informed consent.
Patient is between 18 and 75 years of age, inclusive.
Male > 18 years of age
Performance status < 90% in patients 70 years old or greater, < 80% in patients less than age 70 years
Karnofsky performance status >= 50% for patients > 16 years of age, or Lansky performance status >= 50% for patients =< 16 years of age.
Age ? 18 years.
Age 6 months - 29.99 years at enrollment
be over age 18
?18 years of age
Age (at the time of consent/assent): ?16 years of age
Female subjects who are at least 18 years of age at the time of informed consent
Patient must have Karnofsky >= 60% for patients > 10 years of age; Lansky Play Scale >= 60 for children =< 10 years of age
Patients must have a performance status of 0, 1 or 2; use Karnofsky >= 60 for patients > 16 years of age and Lansky >= 60 for patients =< 16 years of age
< 30% for patients < 60 years,
At least 18 years of age.
DONOR: Age =< 60 years of age
Age ?18 years
Adequate renal function as evidenced by: a) Serum creatinine based on age/gender as below. If serum creatinine is greater than maximum serum creatinine for age/gender as shown in the table below, then creatinine clearance (or radioisotope glomerular filtration rate [GFR]) must be greater than 70 milliliter/minute/1.73 square meter (mL/min/1.73 m2). Maximum Serum Creatinine in milligrams/deciliter (mg/dL) for male: i. Age 2 to less than 6 years = 0.8 ii. Age 6 to less than 10 years = 1.0 iii. Age 10 to less than 13 years = 1.2 iv. Age 13 to less than 16 years = 1.5 v. Age greater than or equal to 16 years = 1.7 Maximum Serum Creatinine (mg/dL) for Female: vi. Age 2 to less than 6 years = 0.8 vii. Age 6 to less than 10 years = 1.0 viii. Age 10 to less than 13 years = 1.2 ix. Age 13 to less than 16 years = 1.4 x. Age greater than or equal to 16 years = 1.4 The threshold creatinine values in this Table were derived from the Schwartz formula for estimating glomerular filtration rate using child length and stature data published by the CDC. b) Urine dipstick less than 2+ for proteinuria. Participants who have greater than or equal to 2+ proteinuria on dipstick urinalysis should undergo a spot protein-creatinine (P/C) ratio that should be Grade less than 2. c) No clinical evidence of nephrotic syndrome.
? 18 years of age.
DONOR: Must be 18-80 years of age, inclusive
Age > 18 years at time of study entry
Performance status: Karnofsky >= 50 for patients > 16 years of age; Lansky >= 50 for patients =< 16 years of age
Age ? 80 years
Age < 80 years and at least 1 of the following conditions:
Patients must have a performance status of >= 70; (Karnofsky if > 16 years and Lansky if =< 16 years of age)
Patients must be > than 12 months and ? 21 years of age at the time of study enrollment.
Karnofsky ? 50% for patients > 16 years of age and Lansky ? 50 for patients ? 16 years of age.
Patients age 18 to 70 years old; eligibility for pediatric patients will be determined in conjunction with an MD Anderson Cancer Center (MDACC) pediatrician; patients age 2-17 years may be enrolled after at least 10 adults (ages 18-70 years old) have been assessed for safety at day 30
Are at least age 18 at screening (Visit 1)
Patient must be > 18 years
Age < 60 years
DONOR: Age >= 18 years
Age-adjusted serum creatinine < 1.5 x normal for age
Age: ? 21 years at the time of diagnosis.
There are no age restrictions
Any patient with both metastatic ependymoma and age < 3 years at the time of enrollment
Age <18-years-old.
Age 12 months to <21 years
Age ? 50
At least 18 years of age
Patient is < 18 years of age
For Phase I Only: Age >/=18 years
MATCHED RELATED DONOR: Age less than 6 years or greater than 70 years
Age: up to and including 18 years at diagnosis of Haemophagocytic Lymphohistiocytosis
DONOR: At least 18 years of age
DONOR: Age >= 0.5 years
Patients must have a performance status of >= 70; (Karnofsky if > 16 years and Lansky if =< 16 years of age
Must be > = 50 years of age.
Age > or = 15 years
Age ? 18 years
Men and women patients 18 years of age and up
Age > 18
Age at least 18 years.
Must be 2 - 45 years of age and at least 10 kg
Age between 18 and 75 years, inclusive.
Age ? 18 years
Group B: Individuals > 70 years of age with previously untreated AML or individuals < 70 years of age with previously untreated AML who refuse or are unable to receive cytarabine as determined by the treating physician
Patients must have a Lansky performance status of >= 30 for children =< 10 years of age or a Karnofsky performance status of > 30 for children > 10 years of age
Patients must have adequate renal function defined as < 1.5 x normal serum creatinine as adjusted for age:\r\n* 0.8 mg/dl for < 5 years of age\r\n* 1.0 mg/dL for > 5 and < 10 years of age\r\n* 1.2 mg/dL for > 10 and < 15 years of age\r\n* 1.5 mg/dL for > 15 years of age\r\n* Or a calculated or measured creatinine clearance or radioisotope glomerular filtration rate (GFR) > 70 ml/min/1.73m^2 obtained within 14 days prior to registration
Age: \r\n* Stratum I (TMI containing arm): 18-60 years of age\r\n* Stratum II (non TMI arm): 18-70 years of age
Patients must have a performance status of >= 70; (Karnofsky if > 16 years and Lansky if < 16 years of age)
DONOR: Age >= 12 years
DONOR: Age >= 12 years of age
Age > 16 years.
Age ?18 years at the time of signing the informed consent form.
Performance status: Karnofsky >= 80% (subjects >= 16 years of age); Lansky >= 80% (for subjects 10-15 years of age)
Aged =< 3 years at diagnosis (not age of transplant)
Must be < 70 years old with no matched 5/6 or 6/6 sibling donor; patients >= 70 and =< 75 years of age may be eligible if they have a co-morbidity score =< 2
Patients must be >18 years of age.
At least 18 years of age
Participants must be > 18 years of age
Age ? 18 years old.
Performance level: Lansky ? 50% for patients ? 16 years of age and Karnofsky ? 50% for patients > 16 years of age.
Age: ?12 months to <18 years old at the time of informed consent
Age ?18 years;
Performance status greater than or equal to (>=) 70 by Lansky scale (for participants less than [<] 16 years of age) or Karnofsky scale (for participants [>=] 16 years of age)
within the last 5 years OR
Patients <18 years of age
Postmenopausal defined as women >54 years of age with amenorrhea for ? 2 years prior to screening
Age of at least 18 years.
Men and women, ? 18 years of age
>18 years
Age ? 18 years at the time of screening or age of consent according to local law
age <18 years;
Between 18 and 80 years of age inclusive, at the time of signing the informed consent.
Age ?18 years at the screening visit.
Be > 18 years of age on day of signing informed consent.
Age 55 years and 1 year or more of amenorrhea
Age ? 18 years.
At least 18 years of age.
Age 18-76 years
Post- menopausal female patients, 18 years of age or greater.
Age >18 years of age; male or female.
Age ? 18 years
At least 18 years of age
Patients must be >_18 years of age
Patients must be age >/= 18 years.
Age >/= 18 years.
At least 18 years of age
At least 18 years of age
At least 18 years of age
Age > 18 years. Because no dosing or adverse event data are currently available on the use of AR-67 in patients < 18 years of age, children are excluded from this study but will be eligible for future pediatric single-agent trials, if applicable.
Age ? 18 years with HCT comorbidity index < 3
At least 18 years of age.
Age >18 years
Man or woman, age >18 years
Age > 18 years
Age ?18 years;
Patients must be 18 years of age.
Age > = 18 years of age
Age < 18 years of age
Age >18 years
Age between 18 and 70 years, inclusive.
Females at least 18 years of age
Age ? 18 years at time of signing informed consent form.
Stratum 1 (IDH wild-type): Patients must be >= 3 years of age and =< 21 years of age at the time of enrollment
Stratum 2 (IDH mutant): Patients must be >= 3 years of age and =< 25 years of age at the time of enrollment
Minimum age 18 years (in Japan, minimum age 20 years).
Age ?18 years at the time of consent.
Patients must be at least 18 years of age.
Age >/= 12 years
Age ? 2 years.
Age greater than 18 years.
Age ? 18 years old
Age ? 18 years and ? 60 years
Age ? 18 years and ? 75 years
Age >18 years;
PRE-REGISTRATION: Performance level as measured by Karnofsky >= 60% for patients > 16 years of age or Lansky >= 60% for patients =< 16 years of age.
ENROLLMENT: Performance level as measured by Karnofsky >= 60% for patients > 16 years of age or Lansky >= 60% for patients =< 16 years of age.
ENROLLMENT: Creatinine clearance >= 60 mL/min/1.73m^2 (calculated by 24 hour [h] urine collection or nuclear glomerular filtration rate [GFR] scan if 24 h collection is not possible) or a serum creatinine based on age and gender as follows: age 1 month to < 6 months, maximum serum creatinine (mg/dL) male 0.4, female 0.4; 6 months to < 1 year, 0.5, 0.5; 1 to < 2 years, 0.6, 0.6; 2 to < 6 years, 0.8, 0.8; 6 to < 10 years, 1, 1; 10 to < 13 years, 1.2, 1.2; 13 to < 16 years, 1.5, 1.4; >= 16 years, 1.7, 1.4.
Be ? 18 years of age.
Age ?60 or
Age ? 18 years.
The subject must be >= 12 years of age at the time of consent
Age ? 18 years
Age ? 18 years old.
Age >/= 60 years
Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
Age (must have body surface area [BSA] >= 0.55 m^2):\r\n* Phase I: >= 3 and =< 21 years of age\r\n* Phase II: >= 3 and =< 35 years of age
Age ?18 years.
Age > 18 years
DONOR: Age >= 18 to =< 77 years old
DONOR: Age >= 13 years old (yo) and =< 75 years
DONOR: Age less than 18 years
Patients must have a Karnofsky performance level of >= 30 for patients > 16 years of age or a Lansky performance scale of >= 30 for patients =< 16 years of age and life expectancy > 8 weeks
Participants must be ? 18 years of age.
> 85 years of age must be approved by principal investigator
Age ?18 years
Minimum Age 18 years (in certain territories, the minimum age requirement may be\n             higher eg age 20 years in Japan and Taiwan)
Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
Creatinine clearance OR radioisotope glomerular filtration rate >= 70 mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows:\r\n* 0.4 mg/dL (1 month to < 6 months of age)\r\n* 0.5 mg/dL (6 months to < 1 year of age)\r\n* 0.6 mg/dL (1 years to < 2 years of age)\r\n* 0.8 mg/dL (2 years to < 6 years of age)\r\n* 1.0 mg/dL (6 years to < 10 years of age)\r\n* 1.2 mg/dL (10 years to < 13 years of age)\r\n* 1.5 mg/dL (male) or 1.4 mg/dL (female) (13 years to < 16 years of age)\r\n* 1.7 mg/dL (male) or 1.4 mg/dL (female) (>= 16 years of age)
DONOR: 14-75 years of age
Age:\r\n* Part A1: Patients must be >= 12 months and < 18 years of age at the time of study enrollment\r\n* Part A2: Patients must be > 6 months and < 12 months of age at the time of study enrollment; patients will enroll one dose level behind the dose level at which patients in Part A1 are enrolling
Age:\r\n* Phase 1 (Part A)\r\n** Patients must be > than 12 months and =< 21 years of age at the time of study enrollment\r\n* Phase 2 (Part B and Part C)\r\n** Patients must be > than 12 months and =< 30 years of age at the time of study enrollment
ECOG 0, 1 or 2, or for children =< 10 years of age, Lansky >= 60
Greater than age-adjusted normal serum creatinine (see below) and a creatinine clearance < 60 mL/min/1.73 m^2\r\n* =< 0.8 mg/dL (age =< 5 years)\r\n* =< 1.0 mg/dL (5 years < age =< 10 years)\r\n* =< 1.2 mg/dL (age > 10 years)
Creatinine below age-adjusted maximum limits in the table below OR creatinine clearance >= 60 mL/min/1.73 m^2 assessed within seven (7) days prior to the start of therapy\r\n* 0.8 mg/dl (patients =< 5 years of age)\r\n* 1.0 mg/dl (patients 5 < age =< 10 years of age)\r\n* 1.2 mg/dl (patients 10 < age =< 15 years of age)\r\n* 1.5 mg/dl (patients > 15 years of age)
DONOR: Age >= 0.5 years
Age (at the time of consent/assent): ?6 months to ?21 years
Cohort 4 only: ?10 years to ?21 years
If <12 years of age: Lanksy Performance Status >50%
Age 18 - 80 years; age > 80 allowed at investigator discretion if performance status ? 1; and each organ system score ? 2 using cumulative illness rating scale (CIRS)
Age ? 18 years or the minimum legal adult age (whichever is greater) at the time of Informed consent.
Men and women ? 18 years of age
18 years of age at the time of signing informed consent
Subjects must be ?18 years of age.
Subject must be ?18 years of age.
Men and Women ? 18 years of age
Patients must be > 24 months and < 30 years of age when registered on study.
Patients must be > 2 years and < 30 years of age when registered on study.
Women and men ?18 years of age with performance status of 0 or 1
Patient must be ?18 years of age
Participants who are newly diagnosed and not considered for high-dose chemotherapy due to: being age >=65 years; or participants less than (<) 65 years with presence of important comorbid condition(s) likely to have a negative impact on tolerability of high dose chemotherapy with stem cell transplantation. Sponsor review and approval of participants below 65 years of age is required before randomization
Age 3 at the time of initial diagnosis to age 21 at the time of initial diagnosis
Karnofsky (age ? 16 years) or Lansky (age < 16 years) performance status ? 50 at screening
Demographics show age < 11
Men and women ?18 years of age.
Must be at least 18 years of age
Men and women ? 18 years of age.
Men and women: ? 65 years of age OR > 18 and < 65 years of age, provided that they meet at least one of the following criteria:
Age ?18 years
Age ?18 years.
Men and women 18 to 85 years of age, inclusive.
Age ? 13 years.
Age at diagnosis at least 18 years.
Age ? 18 years old
Male, age 45 to 80 years
Age ? 55 years and one year or more of amenorrhea
Renal function defined as: A serum creatinine based on age/gender as follows: Maximum Serum Creatinine (mg/dL). Age Male Female 1 to < 2 years 0.6 0.6 2 to < 6 years 0.8 0.8 6 to < 10 years 1.0 1.0 10 to < 13 years 1.2 1.2 13 to < 16 years 1.5 1.4 ? 16 years 1.7 1.4.
Age 3 at the time of screening to age 21 at the time of initial diagnosis
Karnofsky (age ? 16 years) or Lansky (age < 16 years) performance status ? 50 at screening.
Be ?18 years of age;
? 18 years of age.
Age ? 18 years
Women ? 18 and ? 75 years of age.
The patient must be ?18 years of age
Men and women ? 18 years of age.
Patients must be ?18 years of age
Age >= 70 years
? 18 years of age
Patients must be ? 18 years of age
Age 18 years and above
< 55 years of age
Age (at the time of consent) ?18 years of age
?45 years of age and has not had menses for over 2 years
Age ? 18 years
Age ? 18 years.
Subject is ?18 years of age
Age ?18 years at the time of screening
Patients ?18 years of age;
? 18 years of age
Age >18 years
At least 15 years of age Except: where local regulations and/or institutional policies do not allow for subjects < 18 years of age (pediatric population) to participate. For those sites, the eligible subject population is ? 18 years of age
Men and women 18 years of age to 80 years of age of any ethnic origin or race at the time of signing the ICD.
Age >21 years
Have an ECOG performance status of 0-2 for ? 16 years of age and a Lansky performance status of 70-100 for < 16 years of age
? 18 years of age.
Age ? 18 years of age at the time of signing the informed consent document.
Patients must be ? 18 years of age.
Age ? 60 years
Patients must be ? 18 years of age.
Age ? 18 years.
Age superior or equal to 18 years or country's legal age of majority if the legal age is superior to 18 years old.
Age ? 60 years
Men and women ? 18 years of age.
Age ? 18 years
At least 18 years of age
Age
Patients must be ? 12 months of age and ? 30 years of age at the time of study entry for patients diagnosed with DIPG.
Patients must be ? 12 months of age and ? 21 years of age at the time of study entry for patients diagnosed with HGG.
Patients 2-17 years of age must have a blood pressure that is ? 95th percentile for age, height and gender at the time of enrollment.
Men ? 18 years of age at the time of informed consent.
Age ? 50;
Men & women ?20 years of age
Age > = 18 years
Age ?18
? 18 years of age
Adult women (? 18 years of age) with advanced TNBC.
Age ? 18 years.
Female, age ? 18 years
Are at least 18 years of age at the time of informed consent
Men and women ? 18 years of age
Men and women ? 18 years of age
At least 18 years of age
All patients must be at least 18 years of age
Age >= 18 years
Age ? 18 years.
Age ?18 years at the time of signing the informed consent document.
Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
Patients must be >/= 18 years of age.
Subject is < 18 years of age.
Patient of age between 50 to 75 years, inclusive.
Age > 18 years at the time of consent.
Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores 0, 1, or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
Age ? 18 years old
Age ? 18 years.
Male or female, greater than or equal to (>=) 18 years of age (or having reached the age of majority according to local laws and regulations, if the age of majority is > 18 years of age); [i.e. >= 20 years of age in Japan])
Age ? 15 years and < 71 years at the time of signing the informed consent form
Subjects ? 18 years of age must have the ability to give informed consent according to applicable regulatory and local institutional requirements. Legal guardian permission must be obtained for subjects < 18 years of age. Pediatric subjects will be included in age appropriate discussion in order to obtain assent.
Subject is ? 75 years of age.
Be at least 55 years of age
Patients must be ? 18 years of age.
Lansky (age < 16 years at the time of assent/consent) or Karnofsky (age ? 16 years at the time of assent/consent) performance status ? 80 at screening
Male or female patients age ? 18 years of age at the time of informed consent
Age ?18 years.
Patient is at least 18 years of age at randomization.
Participant is ? 18 years of age at the time of signing the informed consent form.
Women ? 18 years of age.
Age ?18 years (? 20 years in Japan).
Age: at least 20 years of age
Female patients must have a bone age of equal to or greater than 12 years of age as determined by local read of appropriate radiographic imaging
Male patients must have a bone age of equal to or greater than 14 years of age as determined by local read of appropriate radiographic imaging
Cohort 1 patients must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\r\n* Note: patients in Cohort 1 will be stratified as follows:\r\n** Stratum 1: Patients >= 11 years of age but < 18 years\r\n** Stratum 2: Patients >= 11 years of age but < 50 years
Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
Men and women ? 18 years of age
Age ? 18 years
Men and women ? 18 years of age
Age ?18 years.
Age >/= 18 years
Be ? 18 years of age on day of signing informed consent.
Age ? 18 years.
Men and women ? 18 years of age
Age ? 18 years at the time of consent
Adults ? 18 years of age.
Age ?18 years;
Patients must be ? 18 years of age.
Age ?18 years
Men and women ? 18 years of age.
Age ?18 years
Men and women ? 18 years of age
Men and women ? 18 years of age.
Age ? 18 years.
Age at least 18 years.
Men and women ? 18 years of age.
Age ? 18 years.
Subject must be ?18 years of age.
Age greater than18 years
? 18 years of age
Male subjects of age ? 18 years
Men and women, ages ? 18 years of age
Age <18-years-old.
?18 years of age.
Age ? 18 years of age
Age ?18 years.
Serum creatinine =< 1.5 x the upper limit of normal for age, or calculated creatinine clearance or nuclear glomerular filtration rate (GFR) >= 70 ml/min/1.73 m^2\r\n* =< 0.6 mg/dL (1 to < 2 years of age)\r\n* =< 0.8 mg/dL (2 to < 6 years of age)\r\n* =< 1.0 mg/dL (6 to < 10 years of age)\r\n* =< 1.2 mg/dL (10 to < 13 years of age)\r\n* =< 1.4 mg/dL (females >= 13 years of age)\r\n* =< 1.5 mg/dL (males 13 to < 16 years of age)\r\n* =< 1.7 mg/dL (males >= 16 years of age)
Age ?60
Age 21 years or younger at the time of initial ALL diagnosis and age > 1 year at the time of study treatment initiation.
Age ? 18 years (Age ? 12 years for patients with bone sarcomas).
Age ? 18 years at the time of consent.
Age: >=18 years of age at the time of providing informed consent.
At least 18 years of age
Minimum age in Japan is 20 years.
Age ?18 years
2 years to 21 years of age
Serum creatinine based on age, or creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 50 ml/min/1.73m^2 (GFR >= 40 ml/min/1.73m^2 if < 2 years of age)\r\n* Maximum serum creatinine based on age\r\n** 0.8 mg/dL (=< 5 years of age)\r\n** 1.0 mg/dL (5 to =< 10 years of age)\r\n** 1.2 mg/dL (10 to =< 15 years of age)\r\n** 1.5 mg/dL (> 15 years of age)
Age ? 18 years.
Age >= 60 years and not candidates for conventional cytotoxic chemotherapy or refuse it; OR patients below the age of 60 years who are considered unfit and/or unable to tolerate standard chemotherapy at the discretion of the treating physician or the principal investigator
Patients must be ? 18 years of age.
Up to 65 years of age
Age >= 18 years
Age <18-years-old.
Age > 18 years
Age ?18 years.
Male patients >/= 18 years of age
? 18 years of age
A serum creatinine based on age/gender as follows:\r\n* =< 0.6 mg/dL (for 1 to < 2 years of age)\r\n* =< 0.8 mg/dL (for 2 to < 6 years of age)\r\n* =< 1.0 mg/dL (for 6 to < 10 years of age)\r\n* =< 1.2 mg/dL (for 10 to < 13 years of age)\r\n* =< 1.4 mg/dL (for females >= 13 years of age)\r\n* =< 1.5 mg/dL (for males 13 to < 16 years of age)\r\n* =< 1.7 mg/dL (for males >= 16 years of age)
? 18 years of age.
Age < 18-years-old.
Adult patient, >/= 18 years of age
At least 18 years of age.
Men or women ?18 years of age
Males and female subjects ? 18 years of age at the time of enrollment, except in Japan where subjects must be ? 20 years of age at the time of enrollment
Age >= 65years.
Men & women ? 18 years of age
DONOR: Age >= 18 years and =< 60 years
Age 60-75 years at the time of diagnosis of AML
Be at least 18 years of age
Men & women ?18 years of age
Men & women ?18 years of age
Age > 21 years
Subjects age ?18 years
Age >/= 60 years
DONOR: 18 to 75 years of age
DONOR: At least 18 years of age
>= 18 years of age
Age of >/= 18 years.
?18 years of age
Patients ?18 years of age.
Age ? 18 years of age
Age > 60 years
6 months to less than 18 years of age at the time of consent.
Age at least 18 years at enrollment.
Females 18 to 80 years of age
Subjects younger than 18 years of age
Age ?18 years
Age > = 18 years at the time of signing the informed consent form.
Age >= 18 years.
Female gender and age ? 18 years at time of study entry
Patients must be ? 15 years of age.
DONOR: 14-75 years of age
Age >=18 years at the time of consent.
Age ?18
At University of Oklahoma: age > 17 years old and =< 55 years for recipient
18F FLT CANDIDATE TRANSPLANT RECIPIENT: Age >= 18 years old at National Cancer Institute (NCI), and age > 4 years and < 24 years at Children’s National Medical Center
At least 18 years of age;
E 05. Less than 18 years (or country's legal age of majority if the legal age is >18 years).
Eighteen years of age or above
Age >=18 years old
Age > than 18 years at the time of signing the informed consent form.
Women (regardless of menopausal status) or men ?18 years of age (or per local regulations).
Unable to receive intensive chemotherapy regimens at enrollment, based on one of the following: I. Age ? 75 years, or II. Age < 75 years with at least 1 of the following co-morbidities:
Age ?18 years.
Age ?18 years.
Age ? 12 years
Male ?18 years of age.
Be ? 18 years of age at time of consent
Subjects 70 years of age or older; OR subjects 60-69 years of age who have one or more comorbidities.
Age > 18 years
Patients under the age of 18.
For ESFT patients age ?12 years.
For ESFT patients age ?12 years.
Age ?18 years (non-ESFT candidates)
Age >=18 years
Age ? 65 years
DONOR: Children less than 12 years of age.
age ?40 years through ?85 years of age;
Age ? 18 years
Age < 3 years at time of diagnosis for all histological diagnosis
Patients less than 3 years of age at diagnosis must meet one of the two following criteria:
Age < 30 years
Age >/= 18 years
Age >= 16 years (age > 18 years to participate in optional symptom burden assessment)
DONOR: Age < 12 years
DONOR: Age less than 12 years
Age ? 18 years
Age ?18 years.
Age ?18 years of age.
Age 18 years.
Women ? 18 years of age
Age ? 18 years at the time of consent.
Age ? 18 years at the time of consent
?18 years of age
Subject is 18 years of age or more at the time of signing the Informed Consent Form
18 years of age.
Minimum age 18 years (in certain territories, the minimum age requirement may be higher (e.g. 20 years in Japan and Taiwan)
Men and women ? 18 years of age.
Age ? 18 years.
Karnofsky > 50% for patients > 16 years of age and Lansky > 50% for patients ? 16 years of age.
Female subjects with age ? 18 years
ECOG 0-2 or Karnofsky ? 50% for patients > 16 years of age; Lansky ? 50% for patients ?16 years of age.
DONOR: Age < 60 years
DONOR: Age: less than age 18 or older than age 60
Age ? 18 years old.
Age ? 18 years
Men and women ? 18 years of age.
>18 years of age.
Female participants of non-childbearing potential, ?18 years of age
Patients must be >18 years of age
Age <18-years-old.
Age >/= 18 years.
Age ? 18 years old.
? 6 months and < 25 years of age
Subjects ? 16 years of age: Karnofsky ? 60% (Appendix A)
Subjects < 16 years of age: Lansky scale ? 60% (Appendix A)
Patients > 18 years of age must have the ability to give informed consent according to applicable regulatory and local institutional requirements. Legal guardian permission must be obtained for patients < 18 years of age. Pediatric patients will be included in age appropriate discussion in order to obtain assent
Age >/= 18 years
?18 years of age
Subjects at least 18 years of age
Age < 55 years old and > 4 months
Age >=18 years (For subjects in Taiwan, Age >= 20 years)
DONOR: age >= 18 years old
Must be ?18 years of age
MSC DONOR: age >= 18 years, =< 30 years
Patients over 18 years of age, regardless of race of gender
? 18 years of age.
7. Age ?18 years.
At least 18 years of age
Male participants who are ?18 years of age
Age ? 18 years.
Age ? 18 years.
Age > or = to 16 years
Age >= 50 years and postmenopausal with no menses for at least one year prior to study enrollment
Caregiver: Age >= 18 years
Age ? 18 years
Pediatric participants, 12 to 17 years of age inclusive
Age >= 18 years.
Age ? 18 years
Age 8-16 years old at the time of consent
Be ? 18 years of age on day of signing informed consent.
Age ?21 years
Age ? 18 years
Age 19 years or older (age of consent in Nebraska); age 18 years or older (applicable to states where the age of majority is 18)
Adult subjects; age ? 18
Subjects ? 18 years age and ? 80 years of age at the time of signing the informed consent form.
Patients younger than 15 years of age
Age ?18 years.
Age ?18 years
Age ? 18 years;
Patient is at least 18 years of age.
Age ?18 years
Patients ? 18 years of age.
Age > or = to 21 years
Age 18 to 70 years of age.
?18 years of age.
Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
DONOR: At least 18 years of age
At least 18 years of age.
Age >/= 18 years
Age ?18 years
Age ?18 years
Men and women ? 18 years of age
Adult patients, >/= 18 years of age
Age between 18 and 75 years old (both inclusive)
12 < 18 years of age
Patient must be ? 18 years of age.
13 to 17 years of age inclusive at screening.
Adult patients, >/= 18 years of age
Patients must be ? 21 years of age at the time of enrollment.
Karnofsky > 50% for patients > 16 years of age and Lansky > 50% for patients less than or equal to 16 years of age. (See Appendix I for Performance Scales).
Age ? 18 years
Age>18
Age ? 18 years.
Female, ?18 years of age
Age >= 18 years
Age >21 years
At least 18 years of age.
Age ? 18 years
Age ? 18 years.
Age ? 18 years.
Age ? 18 years. .
Age ? 18 years.
Age ? 18 years
Age ?21 years
Age ? 18 years of age at the time of signing the Informed Consent Form.
Subject must be ?18 years of age
Participant’s age is 1 to 39 years, inclusive; (St. Jude participants must be aged 1 to 25 years)
Be at least 18 years of age at the time of consent
Age ?18 years.
DONOR: At least 18 years of age
Be at least 18 years of age
Age ? 18 to ? 80 years at the time of signing the informed consent form
At least 18 years of age
Age >= 18 years
Age: >3 months to <18 years of age.
Age ? 18 years
Age ? 18 years.
Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
Age ?18 years
? 18 years of age
At least 18 years of age at time of study entry
At least 18 years of age
Age ? 18 years of age, at the time of informed consent.
Age <18 years.
Men and women ?18 years of age
Age >18 years of age.
Age ?18 years
? 18 years of age
Age ?18 years
Age >21 years
? 18 years of age.
Age between 18 and 75 years
Age ? 18 years.
Age >=18 years
Adult patient, >/= 18 years of age
Age ?18 years
Age >=18 years
Subject must be at least 18 years of age.
Age 18 years or above
Patients must be men and women >= 18 years of age.
Adult participants, >/= 18 years of age
Adult patients, >/= 18 years of age
?18 years.
Women ? 18 years of age
Age >/=18 years old.
Age 4 through 65 years
Men and women ? 18 years of age
Eighteen years of age or above
-  Age >18 years.
Is 0 months (at least 37 weeks gestation) to <18 years of age
Age ? 18 years.
Age ?12 years
Age <18 years.
Patients must be < 30 years of age when registered on study.
Patients must have a life expectancy of at least 8 weeks and a Lansky (< 16 years age) or Karnofsky (> 16 years age) score of at least 50
Age-adjusted serum creatinine 1.5 x normal for age/gender
? 18 years of age
Male or female between one month and <18 years of age (inclusive) at the time of signing the informed consent form (Part C and Part D between 12 months and <18 years of age, inclusive).
For the initial dose escalation to identify the maximum tolerable or PK target dose, age between 2 years and <18 years (inclusive) at the time of signing the informed consent form. Children < 2 years of age will be enrolled once the age specific expansion cohorts are open.
Age between 16
Normal creatinine for age:\r\n* =< 0.8 mg/dL (age =< 5 years)\r\n* =< 1 mg/dL (age 6 to =< 10 years)\r\n* =< 1.2 mg/dL (age 11 to =< 15 years)\r\n* =< 1.5 mg/dL (age >= 16 years)\r\nOR
Be ?18 years of age.
Adults > 18 years of age
DONOR: At least 18 years of age
Age ? 18 years
Adult patients, >/= 18 years of age
Patients must be > 18 years of age
Age of </= 18 years.
Age 14-21
Age ? 18 years of age
Patient is ? 18 years of age on the day of consent signature
Age and Reproductive Status
At least 18 years of age
Donor must be 18 to 70 years of age inclusive.
Recipient must be 18 to 75 years of age inclusive.
Age ? 18 years.
18 years of age
Age > or = to 18 years.
Patient is ?18 years of age.
Must be ? 18 years of age
Age ?18 years
Age ?18 years
Age ? 18 years.
Must be at least 18 years of age
Age ?18 years.
at least 18 years of age
Must be at least 18 years of age
Age ? 18 years
Age > 18 years at the time of consent.
Patients must be female at least 18 years of age.
Patients above >= 65 years old should have an age-adjusted co-morbidity index of =< 3
Age >/= 18 years.
DONOR: Age 18 years to 80 years
Participants must be < 31 years of age at the time of study entry\r\n* Participants currently on therapy at St. Jude, or within 3 years of completing therapy at St. Jude must be =< 24 years of age\r\n* Other participants must be =< 21 years of age
Performance status: Karnofsky > 50% for >= 16 years of age; Lansky > 50% for children < 16 years of age
The participant is age ? 18 years
Patient is ? 15 and < 75 years of age.
Performance status: Karnofsky >= 50 for > 10 years of age; Lansky >= 50 for children =< 10 years of age
Age ? 18 years at the time of signing consent
1 to < 18 years of age
Performance status: Karnofsky ? 60% for 12 to <18 years of age; Lansky play scale ? 60% for 1 to < 12 years of age.
Performance status - Lansky 30-100% (? 16 years of age)
Patients must be greater than 18 years of age
Age ? 18 years
Age ? 18 to ? 80 years at the time of signing the informed consent form
Creatinine clearance >= 70mL/min/1.73m^2 or serum creatinine based on age/gender as follows:\r\n* =< 0.4 mg/dl (age 1 month to < 6 months)\r\n* =< 0.5 mg/dl (age 6 months to < 1 year)\r\n* =< 0.6 mg/dl (age 1 year to < 2 years)\r\n* =< 0.5 mg/dl (age 2 years to < 6 years)\r\n* =< 1.0 mg/dl (age 6 years to < 10 years)\r\n* =< 1.2 mg/dl (age 10 years to < 13 years)\r\n* =< 1.4 mg/dl (females >= 13 years)\r\n* =< 1.5 mg/dl (males 13 years to < 16 years)\r\n* =< 1.7 mg/dl (males >= 16 years)
Patients must be post-menopausal; post-menopausal will be defined as women meeting any of the following criteria:\r\n* >= 60 years of age; or\r\n* < 60 years of age and amenorrheic for >= 12 months prior to day 1 if uterus/ovaries are intact; or\r\n* < 60 years of age, and the last menstrual period 6-12 months prior to day 1, if intact uterus/ovaries and meets biochemical criteria for menopause (follicle-stimulating hormone [FSH] and estradiol within institutional standard for postmenopausal status); or\r\n* < 60 years of age, without a uterus, and meets biochemical criteria for menopause (FSH and estradiol within institutional standards for postmenopausal status); or\r\n* < 60 years of age and history of bilateral oophorectomy; surgery must have been completed at least 4 weeks prior to day 1; or\r\n* Prior radiation castration with amenorrhea for at least 6 months
The parent must be at least 18 years of age to ensure the age of majority across all participating sites to legally consent their child
15 to 39 years of age at diagnosis of first cancer
Age 18 years or more
Age ? 18 years at the time of screening.
Subject is ?18 years of age at the time of signing the study informed consent.
Karnofsky performance status >= 50% for patients >= 16 years of age and Lansky >= 50% for patients < 16 years of age
Age ? 22
Prostate cancer diagnosed at age =< 55 years
PATIENT: >= 65 years
Be over 18 years of age
Age 18 years of age or older at last transplant
The child is 3-8 years of age at time of enrollment
One parent (? 18 years of age) can be present for all sessions
EXCLUSION FOR PARENTS: Parent is < 18 years of age
EXCLUSION FOR PARENTS: Patient is < 2 years of age, or > 24 years of age
EXCLUSION CRITERIA FOR PATIENTS: Patient is < 2 years of age, or > 24 years of age
Co-survivors must be over the age of 18 years
PATIENTS: Age 30-89 years
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 OR a serum creatinine based on age/gender as follows:\r\n* =< 0.4 mg/dL (age 1 month to < 6 months)\r\n* =< 0.5 mg/dL (age 6 months to < 1 year)\r\n* =< 0.6 mg/dL (age 1 to < 2 years)\r\n* =< 0.8 mg/dL (age 2 to < 6 years)\r\n* =< 1 mg/dL (age 6 to < 10 years)\r\n* =< 1.2 mg/dL (age 10 to < 13 years)\r\n* =< 1.4 mg/dL (females age >= 13 years)\r\n* =< 1.5 mg/dL (males age 13 to < 16 years)\r\n* =< 1.7 mg/dL (males age >= 16 years)
Child: child is age 5 to 17 years, 11 months
Age\r\n* For centers that will use fluconazole as the antifungal comparator:\r\n** Age >= 3 months and < 21 years\r\n* For centers that will use voriconazole as the antifungal comparator:\r\n** Age >= 2 years and < 21 years
Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
For donors >= 18 years of age, ability to give informed consent
Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
Cancer diagnosis prior to 22 years of age, irrespective of current age
Age >= 18 years
Female, Age ?18 years.
DONOR: Age >= 18 to =< 75 years old
Patient refusal to participate (any age), or parental refusal to participate for patients less than 18 years of age
Be at least 18 years of age
Are between 55 and 85 years of age
Age > 18 years at the time of consent.
Karnofsky >= 50% for patients > 10 years of age and Lansky >= 50 for patients =< 10 years of age
Is ?18 years or the minimum legal adult age (whichever is greater) and ?75 years (at Screening);
For dose-escalation stage (tablets): age at study entry >= 6 years to < 18 years
For dose-escalation stage (suspension): age at study entry >= 6 months to < 18 years. Participants <1 year of age will not be enrolled until >= 6 participants >= 1 year to < 18 years of age have received at least one cycle of therapy with suspension and until safety and pharmacokinetic assessment of these participants have been conducted.
For expansion stage: age at study entry to be >= 6 months (>=6 years if suspension is not available) to < 30 years. Participants >= 6 months to < 1 year of age may not be enrolled until >= 6 participants >= 1 year to < 18 years of age have received at least one cycle of therapy with suspension in the dose-escalation phase and until safety and pharmacokinetic assessment of these participants have been conducted.
Patients age ?60 years who:
Any patient age ? 70 years.
Patients age ?60 years who:
Any patient age ? 75 years.
Caregivers: At least 18 years of age
Age ? 18 years
Subjects must be at least 18 years of age
Over age 18
Age 5-17 years at time of study enrollment
Subject is ?18 years of age.
Under age 21;
< 18 years of age
DONOR: Age >= 18 years
DONOR: Age < 18 years
Bone Mineral Density (BMD) requirements: Osteopenia if under 70 years of age; Osteopenia or normal BMD if over 70 years of age
Must be >= 18, but < 70 years of age with no matched 5/6 or 6/6 sibling donor - patients >= 70 and =< 75 years of age may be eligible if they have a Co-Morbidity score =< 2
Age 40 years old to 74 years old
Patient must have had a cancer diagnosis < 22 years of age, irrespective of current age
Age ? 18 (or legal age of majority for sites outside US).
Patients must be between 18 and 60 years of age
Age >= 18 years
RECIPIENT: Age 18 to 75 years
Age >= 18 years and =< 70 years
Age >= 18 years
Age >= 18 years for the feasibility phase; age >= 10 years old AND >= 50 kg for the phase II portion
Postmenopausal women, defined as:\r\n* Age > 45 with no menses for at least 2 years
Patient is at least 18 years of age
DONOR: Age >= 18 years
DONOR: Age < 18 years
Age ?18 and ?65 years
Age > 75 years
Must be >= 18, but < 70 years of age with no matched 7/8 or 8/8 sibling donor - patients >= 70 and =< 75 years of age may be eligible if they have a co-morbidity score =< 2
Female age 18 to 55 years
Age: 0-21 years at the time of diagnosis.
Age: 0-21 years at the time of diagnosis.
Subject must be female ? 40 years of age
ECOG 0-1, or for children ?10 years of age, Lansky > 60
Ability to give informed consent for patients greater than 18 years of age. For patients less than 18 years of age the legal guardian must give informed consent.
? 18 years of age
Age: 0-21 years at the time of diagnosis.
?18 years of age at the time of signing informed consent
Is 0 (at least 37 weeks gestation) to 17 years of age at time of randomization
50 to 75 years of age
At least 18 years of age
Between 4.0 years and < 11.0 years of age at the time of recruitment
Age ? 55 years and one year or more of amenorrhea
Adult patients at least 18 years of age
Patients with Lansky (age < 16 years) or Karnofsky (age >= 16 years) score < 50 will be excluded
Karnofsky performance status >= 50 for patients >= 12 years of age; for children < 12 years of age, the Lansky play scale >= 50% can be substituted
Individuals who are less than 18 years of age
Signed document of assent obtained if child >= 10 years of age
Karnofsky >= 70 for patients >= 16 years of age, and Lansky >= 70 for patients < 16 years of age
Signed written informed consent (by parent if patient is < 18 years of age, or by patient, if he or she is >= 18 years of age)
Patient assent for those >= 10 years of age and < 18 years of age for whom a parent provides informed consent
Patients age ?18 years old
Age 21-75 years at screening
CHILD: Has a caregiver, >= 18 years of age that is willing to participate in the study
PHASE I: Performance status >= 60 on Karnofsky scale for patients > 16 years of age and > 60 on Lansky scale for patients < 16 years of age
EXPANSION COHORT: Performance status of >= 60 on Karnofsky scale for patients > 16 years of age and > 60 on Lansky scale for patients =< 16 years of age
Age less than 18 years.
Age < 18 years
Female over 21 years of age;
Age ? 18 years
Patients must have a performance status of >= 50 using the Karnofsky scale for patients > 16 years of age and the Lansky scale for patients =< 16 years of age
Age ? 18 years
Age ?18 years.
Age at treatment 1 to 35 years.
Male or females with an age ? 18 years (? 20 years in Japan)
Is at least 18 years of age at the time of consent
Patients over the age of 18.
Age > 18 years
NORMAL VOLUNTEERS: Be >= 18 years of age
Adult male >/= 18 years of age
Age ? 18 years.
Pediatric patients of any age are eligible, including those that may require sedation for MRI; more specifically, children 0-17 years of age and adults >= 18 years of age are eligible
18 years of age or over.
Participants must be at least 18 years of age
Patients who are at least 18 years of age
Age >/= 18 years
Under 50 or over 74 years of age
Adult patients over 18 years of age;
Be age ? 18 years old.
Be ? 18 years of age
Age ? 18 years.
Age: >1 month and <30 years at time of enrollment
Age and Reproductive Status
age 18+
age ? 18 years
Patients are men or women at least 18 years of age.
?18 years
Age > 65 years
age >=18
Age ? 18 years at time of consent (19 years if required by local or state laws)
Age ? 18
Patients must be >18 years-of-age.
?18 years of age
Patient is at least 18 years of age.
Age ? 18 years
Age ? 18 years
